Last reviewed · How we verify

LMWH+Folic acid — Competitive Intelligence Brief

LMWH+Folic acid (LMWH+Folic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant combination with vitamin supplement. Area: Cardiovascular / Hematology.

marketed Anticoagulant combination with vitamin supplement Factor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component) Cardiovascular / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

LMWH+Folic acid (LMWH+Folic acid) — Omar Mamdouh Shaaban. This combination product uses low-molecular-weight heparin (LMWH) to prevent blood clots and folic acid to support cellular function and reduce homocysteine levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LMWH+Folic acid TARGET LMWH+Folic acid Omar Mamdouh Shaaban marketed Anticoagulant combination with vitamin supplement Factor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant combination with vitamin supplement class)

  1. Omar Mamdouh Shaaban · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LMWH+Folic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/lmwh-folic-acid. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: